stockrow
Friday 6 November 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
76.08
11.28
+17.41%
Follow CGON
Alert me
CG Oncology, Inc. (CGON) Revenue growth
CG Oncology, Inc.'s revenue growth over the twelve months to 30 September 2026 was 178.1%, down 76.6 percentage points from fiscal 2025 (254.7%). That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 254.7% | (203.63) |
| FY2024 | 458.3% | 451.52 |
| FY2023 | 6.81% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −3.72% | (2,128.72) |
| Jun 2026 | 2,125.0% | 1,987.50 |
| Mar 2026 | 137.5% | (5,162.50) |
| Dec 2025 | 5,300.0% | 3,899.10 |
| 5 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| CGON CG Oncology, Inc. | 840.8% |
| SRRK Scholar Rock Holding Corporation compare | 213.7% |
| MIRM Mirum Pharmaceuticals, Inc. compare | 42.2% |
| LGND Ligand Pharmaceuticals Incorporated compare | 1.03% |
| PTCT PTC Therapeutics, Inc. compare | −35.1% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| MANE Veradermics Incorporated compare | — |
| IMVT Immunovant, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement